Motor neuron disease-frontotemporal dementia: a clinical continuum

Overlap between motor neuron disease (MND) and frontotemporal dementia (FTD) occurs at clinical, genetic and pathological levels, and has been recently strengthened through the discovery of the C9orf72 genetic expansion. MND is now considered to be a multisystem disorder in which cognitive involvement may be present and, in some cases, may evolve to frank FTD. Identifying cognitive features in MND can be challenging, while, similarly, motor dysfunction in FTD may be overlooked. As such, the present review aims to decipher the variety of overlapping clinical features across the MND–FTD continuum.

[1]  J. Hodges,et al.  Clinical heterogeneity of the C9orf72 genetic mutation in frontotemporal dementia , 2015, Neurocase.

[2]  Sonja W. Scholz,et al.  Multiple system atrophy is not caused by C9orf72 hexanucleotide repeat expansions , 2015, Neurobiology of Aging.

[3]  R. Conwit,et al.  Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial , 2014, The Lancet Neurology.

[4]  Peter K. Todd,et al.  Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS , 2014, Neuron.

[5]  Y. D. van der Werf,et al.  Prefrontal involvement related to cognitive impairment in progressive muscular atrophy , 2014, Neurology.

[6]  M. Kiernan,et al.  A longer diagnostic interval is a risk for depression in amyotrophic lateral sclerosis , 2014, Palliative and Supportive Care.

[7]  J. Rothstein,et al.  Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies , 2014, Trends in Neurosciences.

[8]  E. Huey,et al.  Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72. , 2014, JAMA neurology.

[9]  J. Hodges,et al.  A visual MRI atrophy rating scale for the amyotrophic lateral sclerosis-frontotemporal dementia continuum , 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[10]  J. Hodges,et al.  A novel tool to detect behavioural symptoms in ALS , 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[11]  N. Bresolin,et al.  Antisense Oligonucleotide Therapy for the Treatment of C9ORF72 ALS/FTD Diseases , 2014, Molecular Neurobiology.

[12]  T. Montine,et al.  Absence of C9ORF72 expanded or intermediate repeats in autopsy‐confirmed Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[13]  A. Chiò,et al.  A familial ALS case carrying a novel p.G147C SOD1 heterozygous missense mutation with non-executive cognitive impairment , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[14]  Colin J. Mahoney,et al.  A pathogenic progranulin mutation and C9orf72 repeat expansion in a family with frontotemporal dementia , 2014, Neuropathology and applied neurobiology.

[15]  J. Hodges,et al.  Frontotemporal dementia associated with the C9ORF72 mutation: a unique clinical profile. , 2014, JAMA neurology.

[16]  J. Hodges,et al.  Neuropsychiatric changes precede classic motor symptoms in ALS and do not affect survival , 2014, Neurology.

[17]  D. Mari,et al.  Incomplete penetrance of the C9ORF72 hexanucleotide repeat expansions: frequency in a cohort of geriatric non-demented subjects. , 2014, Journal of Alzheimer's disease : JAD.

[18]  O. Hardiman,et al.  Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial , 2013, The Lancet Neurology.

[19]  Kevin F. Bieniek,et al.  C9ORF72 repeat expansions in cases with previously identified pathogenic mutations , 2013, Neurology.

[20]  L. Petrucelli,et al.  Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study , 2013, The Lancet Neurology.

[21]  C. Broeckhoven,et al.  Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum , 2013, Trends in Neurosciences.

[22]  A. Bokde,et al.  Multiparametric MRI study of ALS stratified for the C9orf72 genotype , 2013, Neurology.

[23]  Z. Zou,et al.  Screening for C9orf72 repeat expansions in Chinese amyotrophic lateral sclerosis patients , 2013, Neurobiology of Aging.

[24]  D. Neary,et al.  Frontotemporal dementia with amyotrophic lateral sclerosis: A clinical comparison of patients with and without repeat expansions in C9orf72 , 2013, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[25]  J. Hodges,et al.  Cortical atrophy in ALS is critically associated with neuropsychiatric and cognitive changes , 2013, Neurology.

[26]  M. Kiernan,et al.  Pathophysiological insights into ALS with C9ORF72 expansions , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[27]  M. Kiernan,et al.  Fasciculation anxiety syndrome in clinicians , 2013, Journal of Neurology.

[28]  C. Yiannikas,et al.  Split-hand index for the diagnosis of amyotrophic lateral sclerosis , 2013, Clinical Neurophysiology.

[29]  F. Pasquier,et al.  C9orf72 repeat expansions are a rare genetic cause of parkinsonism. , 2013, Brain : a journal of neurology.

[30]  Murray Grossman,et al.  Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial , 2013, The Lancet Neurology.

[31]  F. Jessen,et al.  A Pan-European Study of the C9orf72 Repeat Associated with FTLD: Geographic Prevalence, Genomic Instability, and Intermediate Repeats , 2012, Human mutation.

[32]  Michelle K. Lupton,et al.  The C9ORF72 expansion mutation is a common cause of ALS+/−FTD in Europe and has a single founder , 2012, European Journal of Human Genetics.

[33]  Mark Hallett,et al.  Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[34]  J. Hodges,et al.  Caregiver burden in amyotrophic lateral sclerosis is more dependent on patients’ behavioral changes than physical disability: a comparative study , 2012, BMC Neurology.

[35]  L. Goldstein,et al.  Is language impairment more common than executive dysfunction in amyotrophic lateral sclerosis? , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[36]  A. Singleton,et al.  Large C9orf72 repeat expansions are not a common cause of Parkinson's disease , 2012, Neurobiology of Aging.

[37]  J. Hodges,et al.  Grey and White Matter Changes across the Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Continuum , 2012, PloS one.

[38]  M. Schwab,et al.  The role of Nogo-A in axonal plasticity, regrowth and repair , 2012, Cell and Tissue Research.

[39]  Janel O. Johnson,et al.  Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study , 2012, The Lancet Neurology.

[40]  D. Geschwind,et al.  Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[41]  O. Hardiman,et al.  Absence of consensus in diagnostic criteria for familial neurodegenerative diseases , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[42]  D. Neary,et al.  Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. , 2012, Brain : a journal of neurology.

[43]  A. Al-Chalabi,et al.  Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study , 2012, The Lancet Neurology.

[44]  C. Jack,et al.  Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics , 2012, Brain : a journal of neurology.

[45]  Nick C Fox,et al.  Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features , 2012, Alzheimer's & Dementia.

[46]  A. Singleton,et al.  Repeat expansion in C9ORF72 in Alzheimer's disease. , 2012, The New England journal of medicine.

[47]  J. Hodges,et al.  Amyotrophic lateral sclerosis and frontotemporal dementia: A behavioural and cognitive continuum , 2012, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[48]  A. Ludolph,et al.  Amyotrophic lateral sclerosis. , 2012, Current opinion in neurology.

[49]  A. Eisen,et al.  Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p , 2012, Acta Neuropathologica.

[50]  T. Ferman,et al.  Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72 , 2011, Acta Neuropathologica.

[51]  Bruce L. Miller,et al.  Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.

[52]  David Heckerman,et al.  A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD , 2011, Neuron.

[53]  Ammar Al-Chalabi,et al.  Clinical genetics of amyotrophic lateral sclerosis: what do we really know? , 2011, Nature Reviews Neurology.

[54]  Sarah E. MacPherson,et al.  Evidence of Social Understanding Impairment in Patients with Amyotrophic Lateral Sclerosis , 2011, PloS one.

[55]  S. Abrahams.  Social cognition in amyotrophic lateral sclerosis , 2011 .

[56]  J. Hodges,et al.  Motor neuron dysfunction in frontotemporal dementia. , 2011, Brain : a journal of neurology.

[57]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[58]  O. Hardiman,et al.  The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[59]  J. Haines,et al.  Mutations in UBQLN2 cause dominant X-linked juvenile and adult onset ALS and ALS/dementia , 2011, Nature.

[60]  O. Hardiman,et al.  Proposed criteria for familial amyotrophic lateral sclerosis , 2011, Amyotrophic Lateral Sclerosis.

[61]  O. Hardiman,et al.  Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia , 2011, Neurology.

[62]  O. Hardiman,et al.  Amyotrophic lateral sclerosis , 2011, The Lancet.

[63]  M. Inghilleri,et al.  Clinical neurophysiology in ALS. , 2011, Archives italiennes de biologie.

[64]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[65]  J. Hodges,et al.  Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management , 2011, The Lancet Neurology.

[66]  Sarah E. MacPherson,et al.  Deficits in emotional and social cognition in amyotrophic lateral sclerosis. , 2011, Neuropsychology.

[67]  J. Hodges,et al.  Neurobehavioral features in frontotemporal dementia with amyotrophic lateral sclerosis. , 2010, Archives of neurology.

[68]  E. Buratti,et al.  The multiple roles of TDP-43 in pre-mRNA processing and gene expression regulation , 2010, RNA biology.

[69]  G. Repovš,et al.  Amyotrophic lateral sclerosis patients show executive impairments on standard neuropsychological measures and an ecologically valid motor-free test of executive functions , 2010, Journal of clinical and experimental neuropsychology.

[70]  J. Rohrer,et al.  Phenomenology and anatomy of abnormal behaviours in primary progressive aphasia , 2010, Journal of the Neurological Sciences.

[71]  Takeo Kato,et al.  Mutations of optineurin in amyotrophic lateral sclerosis , 2010, Nature.

[72]  M. Gunetti,et al.  Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial , 2010, Experimental Neurology.

[73]  J. Hodges,et al.  How preserved is episodic memory in behavioral variant frontotemporal dementia? , 2010, Neurology.

[74]  K. Sleegers,et al.  Genetic contribution of FUS to frontotemporal lobar degeneration , 2010, Neurology.

[75]  M. York,et al.  Detecting frontotemporal dysfunction in ALS: Utility of the ALS Cognitive Behavioral Screen (ALS-CBS™) , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[76]  M. Kiernan,et al.  FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[77]  E. Beghi,et al.  Incidence of amyotrophic lateral sclerosis in Europe , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[78]  M. Freedman,et al.  Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[79]  A. Chiò.  ISIS Survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis , 1999, Journal of Neurology.

[80]  J R Hodges,et al.  Incidence of early-onset dementias in Cambridgeshire, United Kingdom , 2008, Neurology.

[81]  Peter Heutink,et al.  Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia , 2008, The Lancet Neurology.

[82]  M. Kiernan,et al.  Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. , 2008, Brain : a journal of neurology.

[83]  Nancy Johnson,et al.  Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia , 2008, Annals of neurology.

[84]  B. McConkey,et al.  TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis , 2008, Nature Genetics.

[85]  B. Boeve,et al.  Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN). , 2008, Archives of neurology.

[86]  Xun Hu,et al.  TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis , 2008, Science.

[87]  L. Mazzini,et al.  Stem cell treatment in Amyotrophic Lateral Sclerosis , 2008, Journal of the Neurological Sciences.

[88]  Hiroyuki Nodera,et al.  [New diagnostic criteria of ALS (Awaji criteria)]. , 2007, Brain and nerve = Shinkei kenkyu no shinpo.

[89]  B. Dubois,et al.  Progranulin null mutations in both sporadic and familial frontotemporal dementia , 2007, Human mutation.

[90]  Bruce L. Miller,et al.  Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.

[91]  M. Kiernan,et al.  Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. , 2006, Brain : a journal of neurology.

[92]  Ronald C Petersen,et al.  Clinically undetected motor neuron disease in pathologically proven frontotemporal lobar degeneration with motor neuron disease. , 2006, Archives of neurology.

[93]  H. Mitsumoto,et al.  The natural history of primary lateral sclerosis , 2006, Neurology.

[94]  S. Ennis,et al.  ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis , 2006, Nature Genetics.

[95]  Andrew Kertesz,et al.  The evolution and pathology of frontotemporal dementia. , 2005, Brain : a journal of neurology.

[96]  T. Gillingwater,et al.  A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. , 2004, American journal of human genetics.

[97]  J. Hodges,et al.  Clinicopathological correlates in frontotemporal dementia , 2004, Annals of neurology.

[98]  R. Petersen,et al.  The incidence of frontotemporal lobar degeneration in Rochester, Minnesota, 1990 through 1994 , 2004, Neurology.

[99]  Philip Scheltens,et al.  Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. , 2003, Brain : a journal of neurology.

[100]  M. Sjögren,et al.  The prevalence of frontal variant frontotemporal dementia and the frontal lobe syndrome in a population based sample of 85 year olds , 2003, Journal of neurology, neurosurgery, and psychiatry.

[101]  Catherine Lomen-Hoerth,et al.  The overlap of amyotrophic lateral sclerosis and frontotemporal dementia , 2002, Neurology.

[102]  J R Hodges,et al.  The prevalence of frontotemporal dementia , 2002, Neurology.

[103]  J R Hodges,et al.  Selective impairment of verb processing associated with pathological changes in Brodmann areas 44 and 45 in the motor neurone disease-dementia-aphasia syndrome. , 2001, Brain : a journal of neurology.

[104]  A. Wilbourn,et al.  The “split hand syndrome” , 2000, Muscle & nerve.

[105]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[106]  R. Crowther,et al.  Tau Mutations Cause Frontotemporal Dementias , 1998, Neuron.

[107]  L. Bruijn,et al.  Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. , 1998, Science.

[108]  John R. Hodges,et al.  Fronto-Temporal Lobar Degeneration: Fronto-Temporal Dementia, Progressive Aphasia, Semantic Dementia. , 1997 .

[109]  Julie S. Snowden,et al.  Fronto-Temporal Lobar Degeneration: Fronto-Temporal Dementia, Progressive Aphasia, Semantic Dementia , 1996 .

[110]  B. Brooks,et al.  El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis , 1994, Journal of the Neurological Sciences.

[111]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[112]  J. Hodges,et al.  Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. , 1992, Brain : a journal of neurology.

[113]  A. Hudson.  Amyotrophic lateral sclerosis and its association with dementia, parkinsonism and other neurological disorders: a review. , 1981, Brain : a journal of neurology.